Previous 10 |
home / stock / meobf / meobf news
TG Therapeutics reports development for Umbralisib TG Therapeutics Inc. ( TGTX ) reported that the FDA has accepted its New Drug Application for umbralisib. The drug candidate will be reviewed under the Priority Review pathway. It had been granted Breakthrough Therapy tag for treating ma...
Adam Smith (1723-1790) was not who you think he was. I'm talking about the original Adam Smith who wrote The Wealth of Nations (1776) and spent most of his life in Edinburgh, Scotland. The more recent "Adam Smith" - nom de plume of the late George Goodman who wrote The Money Game (1967) - ...
There are many levels to the coronavirus pandemic and a massive effort is underway to find a vaccine and treatments. Genetic Engineering News summarised 161+ candidates. The US clinical trials website indicates 1,915 trials underway using the keyword COVID-19 (June 3, 2020). The common c...
Mesoblast Ltd (MESO) Q4 2020 Earnings Conference Call May 27, 2020 06:00 PM ET Corporate Participants Silviu Itescu - CEO Josh Muntner - CFO Fred Grossman - CMO Conference Call Participants Louise Chen - Cantor Jeffrey Cohen - Ladenburg Thalmann Jason Folger - Dawson Ja...
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q3 earnings Read more ...
The SARS-CoV2 pandemic has ignited a massive effort across the globe, led by medical researchers and biotech companies, to come up with therapies that can help patients and bring an end to the pandemic. Vaccines, antibodies, immunity and convalescent plasma have all become common medical ter...
Mesoblast Gets FDA Go-Ahead for COVID 19 Treatment Application Mesoblast Limited ( MESO ) announced that the US FDA has cleared its Investigational New Drug application for treating patients suffering from acute respiratory distress syndrome ((ARDS)) due to coronavirus infection using re...
Based on FDA feedback, Mesoblast ( OTCPK:MEOBF ) will conduct a pivotal Phase 3 clinical trial evaluating cell therapy Revascor in patients with end-stage heart failure who have a left ventricular assist device (LVAD). More news on: Mesoblast Limited, Healthcare stocks news, Read mor...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....